```
=> d que  l24
L7                  STR
```




S @10 Ak @11




























```
VAR G1=O/10/SO2/CH2
VAR G2=OH/11/41/CN/12/16/19/23/X/NO2/NH2/25/27/32/36
NODE ATTRIBUTES:
CONNECT IS E2  RC AT  10
CONNECT IS E1  RC AT  11
CONNECT IS E1  RC AT  18
CONNECT IS E1  RC AT  21
CONNECT IS E1  RC AT  24
CONNECT IS E1  RC AT  26
CONNECT IS E1  RC AT  29
CONNECT IS E1  RC AT  31
CONNECT IS E1  RC AT  33
CONNECT IS E1  RC AT  34
CONNECT IS E1  RC AT  38
DEFAULT MLEVEL IS ATOM
GGCAT   IS PCY  UNS  AT   8
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS M2 N  AT   8

GRAPH ATTRIBUTES:
RSPEC   4
NUMBER OF NODES IS  43

STEREO ATTRIBUTES: NONE
L11       266390 SEA FILE=REGISTRY ABB=ON  PLU=ON  NCNC2/ESS AND NCNC3/ESS
L12        41113 SEA FILE=REGISTRY SUB=L11 SSS FUL L7
L17         2955 SEA FILE=HCAPLUS ABB=ON  PLU=ON  FLAVIVIRUS+OLD,NT/CT
L18         3441 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L17 OR FLAVIVIR?
L23        17908 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L12(L)(BAC OR DMA OR PAC OR
                 PKT OR THU)/RL
L24           41 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L18 AND L23
```

answers contain purine ring.



← Cmpds used therapeutically

← 41 Refs.

=> d l24 ibib ab hitstr 1-41

L24 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:387285 HCAPLUS
TITLE: Medicinal preparation having chemotherapeutic encapsulated viral envelope vectors
INVENTOR(S): Yamamoto, Seiji; Kotani, Hitoshi; Kaneda, Yasufumi
PATENT ASSIGNEE(S): Genomidea Inc., Japan; Anges Mg, Inc.
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004039406 | A1 | 20040513 | WO 2003-JP13860 | 20031029 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2002-320577 A 20021101
AB It is intended to provide a medicinal preparation for transferring a chemotherapeutic (preferably an anticancer agent) into cells or the living body by using a virus envelope vector. Namely, a medicinal preparation containing a virus envelope vector having a chemotherapeutic encapsulated therein as the active ingredient. Examples of the anticancer agent include bleomycins, anthraquinone carcinostatic agents, mitomycins, actinomycins, taxane derivs., camptothecins, cisplatins, staurosporines, vincristine, streptozotocin, 5-fluorouracil (5-FU) and its derivs., pirarubicin, dolastatin and pharmacol. acceptable salts thereof. Examples of the virus include sendai virus, retro virus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, pox virus, influenza virus and so on. Bleomycin hydrochloride-encapsulated sendai virus envelop vector was prepared, and tested for its antitumor activity in colon cancer CT26-bearing mice.
IT INDEXING IN PROGRESS
IT **574-25-4**, 6-Mercaptopurine riboside **75607-67-9**, Fludarabine phosphate
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(medicinal preparation having chemotherapeutic encapsulated viral envelope vectors with platinum complex and/or antimetabolites)
RN 574-25-4 HCAPLUS
CN Inosine, 6-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 75607-67-9 HCAPLUS
CN 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-β-D-arabinofuranosyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L24 ANSWER 2 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:183031 HCAPLUS
DOCUMENT NUMBER: 140:234402
TITLE: Recombinant human IL-7 drug substance, its composition and preparation and therapeutic uses thereof
INVENTOR(S): Morre, Michel Christian; Assouline, Brigitte; Cortez, Pierre; Gregoire, Anne
PATENT ASSIGNEE(S): Cytheris, Fr.
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004018681 | A2 | 20040304 | WO 2003-EP8701 | 20030806 |
| WO 2004018681 | A3 | 20040401 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1391513 A1 20040225 EP 2002-291996 20020808

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

PRIORITY APPLN. INFO.: EP 2002-291996 A 20020808
US 2003-475881P P 20030605

AB The present invention relates, generally, to the fields of immunol. and mol. biol. The invention discloses, more particularly, new and improved interleukin-7 drug substances, corresponding specific immunoreactive antibodies, as well as compns. comprising the same, their preparation and uses. Specifically disclosed are a purified recombinant human IL-7 conformer comprising the following three disulfide bridges: Cys:1-4(Cys2-Cys92); 2-5(Cys34-Cys129) and 3-6(Cys47-Cys141). The invention also discloses methods to characterize the impurity profile of a r-hlL-7 drug substance used for therapeutic purpose, as well as optimized nucleotide sequences encoding mammalian IL-7, recombinant expression vectors and methods for preparing and purifying said polypeptides. The present invention stems from the unexpected discovery that the long term activity of recombinant IL-7 is mostly expressed by a specific conformer and that other conformers, potential product-related substances, product-related impurities, and process-related impurities, which would normally be included in the specification of the drug substance and/or drug product, although bioactive, should be strictly minimized because they are able to trigger an immune reaction against the desired IL-7 mol.

IT **2382-65-2**

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses) (adjuvants for recombinant human IL-7; recombinant human IL-7 drug substance, its composition and preparation and therapeutic uses thereof)

RN 2382-65-2 HCAPLUS

CN Guanosine, cytidylyl-(3'→5')- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




L24 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:157517 HCAPLUS

DOCUMENT NUMBER: 140:198092

TITLE: Recombinant human IL-7 drug substance, its composition and preparation and therapeutic uses thereof

INVENTOR(S): Morre, Michel Christian; Assouline, Brigitte; Cortez, Pierre; Gregoire, Anne

PATENT ASSIGNEE(S): Cytheris, Fr.

SOURCE: Eur. Pat. Appl., 53 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 1391513 | A1 | 20040225 | EP 2002-291996 | 20020808 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| WO 2004018681 | A2 | 20040304 | WO 2003-EP8701 | 20030806 |
| WO 2004018681 | A3 | 20040401 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |

PRIORITY APPLN. INFO.: EP 2002-291996 A 20020808
US 2003-475881P P 20030605

AB The present invention relates, generally, to the fields of immunol. and mol. biol. The invention discloses, more particularly, new and improved interleukin-7 drug substances, corresponding specific immunoreactive antibodies, as well as compns. comprising the same, their preparation and uses. Specifically disclosed are a purified recombinant human IL-7 conformer comprising the following three disulfide bridges: Cys:1-4(Cys2-Cys92); 2-5(Cys34-Cys129) and 3-6(Cys47-Cys141). The invention also discloses methods to characterize the impurity profile of a r-hIL-7 drug substance used for therapeutic purpose, as well as optimized nucleotide sequences encoding mammalian IL-7, recombinant expression vectors and methods for preparing and purifying said polypeptides. The present invention stems from the unexpected discovery that the long term activity of recombinant IL-7 is mostly expressed by a specific conformer and that other conformers, potential product-related substances, product-related impurities, and process-related impurities, which would normally be included in the specification of the drug substance and/or drug product, although bioactive, should be strictly minimized because they are able to trigger an immune reaction against the desired IL-7 mol.

IT **2382-65-2**
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(adjuvants for recombinant human IL-7; recombinant human IL-7 drug substance, its composition and preparation and therapeutic uses thereof)
RN 2382-65-2 HCAPLUS
CN Guanosine, cytidylyl-(3'→5')- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:149406 HCAPLUS
TITLE: Excision of Incorporated Nucleotide Analogue Chain-terminators can Diminish their Inhibitory Effects on Viral RNA-dependent RNA Polymerases
AUTHOR(S): D'Abramo, Claudia M.; Cellai, Luciano; Gotte, Matthias
CORPORATE SOURCE: Lady Davis Institute-Jewish General Hospital, McGill University AIDS Centre, Montreal, QC, H3T 1E2, Can.
SOURCE: Journal of Molecular Biology (2004), 337(1), 1-14
CODEN: JMOBAK; ISSN: 0022-2836
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Bovine viral diarrhea virus (BVDV) is amongst the best-characterized members of the **Flaviviridae**, that includes the hepatitis C virus (HCV). The virally encoded RNA-dependent RNA polymerase (RdRp) plays a crucial role during replication and therefore represents an important target for the development of antiviral drugs. Here the authors studied biochem. mechanisms associated with the inhibition of BVDV RNA synthesis by 2'-hydroxyl, 3'-deoxynucleoside triphosphates (3'-dNTPs). All four nucleotide analogs are effectively incorporated and act as chain-terminators. However, relatively low, physiol. relevant concns. of pyrophosphate (PPi) are sufficient to drive the reaction backwards, which results in primer unblocking and rescue of RNA synthesis. Metal ion requirements for nucleotide incorporation and pyrophosphorolysis are similar; the efficiency of both reactions is higher with Mn2+ as compared to Mg2+. Complexes containing chain-terminated primer strands are stable in the presence of heparin, which increases the probability that pyrophosphorolysis occurs before the enzyme can dissociate from its nucleic acid substrate. In contrast to the reverse transcriptase of the human immunodeficiency virus type-1 (HIV-1 RT), the BVDV RdRp may not recruit nucleoside triphosphate (NTP) pools as PPi donors. Conversely, the authors found that the efficiency of primer unblocking is severely compromised in the presence of increasing concns. of the NTP that is complementary to the next template position. These data suggest that the incoming NTP can access its designated binding site, which, in turn, prevents the catalytically competent complexation of PPi. The results of this study provide novel insights into mechanisms involved in pyrophosphorolysis associated with viral RdRps, and suggest that the excision reaction is likely to be an important parameter that can affect susceptibility to nucleotide analog inhibitors directed against viral RdRps.

IT **73-04-1 55968-37-1**
RL: **PAC (Pharmacological activity); THU (Therapeutic**

use); BIOL (Biological study); USES (Uses)
(excision of incorporated nucleotide analog chain-terminators by pyrophosphate can diminish their inhibitory effects on viral RNA-dependent RNA polymerases in relation to divalent metal ions and nucleoside triphosphates)

RN 73-04-1 HCAPLUS
CN Adenosine 5'-(tetrahydrogen triphosphate), 3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 55968-37-1 HCAPLUS
CN Guanosine 5'-(tetrahydrogen triphosphate), 3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:60253 HCAPLUS
DOCUMENT NUMBER: 140:127195
TITLE: Antibodies specifically bind to anionic phospholipids and/or aminophospholipids conjugated with duramycin peptide for treating viral infections and cancer
INVENTOR(S): Thorpe, Philip E.; Soares, Melina M.; Huang, Xianming; He, Jin; Ran, Sophia
PATENT ASSIGNEE(S): Board of Regents the University of Texas System, USA
SOURCE: PCT Int. Appl., 378 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004006847 | A2 | 20040122 | WO 2003-US21925 | 20030715 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-396263P P 20020715

AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compns. and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compns. and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

IT **5536-17-4D**, Vidarabine, conjugates
RL: BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(antibodies specifically bind to anionic phospholipids and/or aminophospholipids conjugated with duramycin peptide for treating viral infections and cancer)

RN 5536-17-4 HCAPLUS

CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L24 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:20697 HCAPLUS

DOCUMENT NUMBER: 140:87662

TITLE: 2'- and 3'-nucleoside prodrugs for treating **Flaviviridae** infections

INVENTOR(S): Sommadossi, Jean-pierre; La Colla, Paolo; Storer, Richard; Gosselin, Gilles

PATENT ASSIGNEE(S): Idenix (Cayman) Limited, Cayman I.; Centre National de la Recherche Scientifique; Universita Degli Studi di

SOURCE: Cagliari
PCT Int. Appl., 2498 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004003000 | A2 | 20040108 | WO 2003-IB3901 | 20030627 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 2002-392350P P 20020628
US 2002-392351P P 20020628
US 2003-466194P P 20030428
US 2003-470949P P 20030514

OTHER SOURCE(S): MARPAT 140:87662

AB 2' And 3'-Prodrugs of 1'-, 2'-, 3'-, or 4'-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivs., are described which are useful in the prevention and treatment of **Flaviviridae** infections and other related conditions. These modified nucleosides provide superior results against **flaviviruses** and pestiviruses, including hepatitis C virus and viruses generally that replicate through an RNA-dependent RNA reverse transcriptase. Compds., compns., methods and uses are provided for the treatment of **Flaviviridae** infection, including HCV infection, that include the administration of an effective amount of the prodrugs of the invention, or their pharmaceutically acceptable salts or derivs. These drugs may optionally be administered in combination or alternation with further antiviral agents to prevent or treat **Flaviviridae** infections and other related conditions. Preparation of compds. of the invention is included.

IT **2096-10-8 15397-12-3 374750-30-8**
**640725-73-1 640725-74-2 640725-75-3**
**640725-76-4 640725-77-5**
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(nucleoside prodrugs for treating **Flaviviridae** infections)

RN 2096-10-8 HCAPLUS
CN Adenosine, 2-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 15397-12-3 HCAPLUS
CN Adenosine, 2'-C-methyl- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 374750-30-8 HCAPLUS
CN Guanosine, 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 640725-73-1 HCAPLUS
CN Adenosine, 2-amino-2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 640725-74-2 HCAPLUS
CN 9H-Purin-2-amine, 6-chloro-9-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 640725-75-3 HCAPLUS
CN L-Valine, 3',5'-diester with 6-chloro-9-(2-C-methyl-β-D-ribofuranosyl)-9H-purin-2-amine, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 640725-76-4 HCAPLUS
CN Adenosine, 2'-C-ethynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 640725-77-5 HCAPLUS
CN Adenosine, 2-amino-N-cyclopropyl-2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **205171-05-7 374750-32-0 565450-78-4**
RL: **PAC (Pharmacological activity); THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(nucleoside prodrugs for treating **Flaviviridae** infections, and use with other agents)

RN 205171-05-7 HCAPLUS
CN 9H-Purine, 6-chloro-9-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 374750-32-0 HCAPLUS
CN Inosine, 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 565450-78-4 HCAPLUS
CN Inosine, 2'-C-methyl-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L24 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:20696 HCAPLUS
DOCUMENT NUMBER: 140:77365
TITLE: Preparation of modified 2'- and 3'-nucleoside prodrugs for treating **Flaviviridae** infections
INVENTOR(S): Sommadossi, Jean-pierre; La Colla, Poalo; Storer, Richard; Gosselin, Gilles
PATENT ASSIGNEE(S): Idenix (Cayman) Limited, Cayman I.; Universita degli studi di Cagliari; Centre National de la Recherche

SOURCE: Scientifique
PCT Int. Appl., 201 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004002999 | A2 | 20040108 | WO 2003-IB3246 | 20030627 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 2002-392350P P 20020628
US 2002-392351P P 20020628
US 2003-466194P P 20030428
US 2003-470949P P 20030514

OTHER SOURCE(S): MARPAT 140:77365

AB 2' And/or 3' prodrugs of 1', 2', 3' or 4'-branched-nucleosides I, wherein R1-R3 are independently H, phosphate, alkyl, acyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonate ester, benzyl, wherein the Ph group is optionally substituted with one or more substituents, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, lipid, amino acid, carbohydrate, peptide, cholesterol; Y1 is hydrogen, bromo, chloro, fluoro, iodo, CN, OH, OR4, NH2, NHR4, NR4R5, SH or SR4; X1 and X2 are independently alkyl, CH3, CF3, CY3, 2-Br-Et, CH2F, CH2Cl, CH2CF3, CF2CF3, CY2CY3, CH2OH, alkenyl, alkynyl, COOH, COOR4, COO-alkyl, COO-aryl, CO-O-alkoxyalkyl, CONH2, CONHR4, CON(R4)2, halo, CN, N3, OH, OR4, NH2, NHR4, NR4R5, SH or SR5; Y is independently H, halo; and each R4 and R5 is independently hydrogen, acyl, alkyl, lower alkyl, alkenyl, alkynyl or cycloalkyl, and their pharmaceutically acceptable salts and derivs. are described. These prodrugs are useful in the prevention and treatment of **Flaviviridae** infections, including HCV infection, and other related conditions. Compds. and compns. of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivs. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat **Flaviviridae** infections and other related conditions. Thus, antiviral activity of β-D-2'-C-methyl-7-methyl-6-phenyl-3,3a,5,8a-tetrahydro-1,3,4,5,7a-penta-aza-s-indacen-8-one is reported.

IT **640281-91-0**
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(preparation of modified and nucleoside prodrugs for treating **flaviviridae** infections)

RN 640281-91-0 HCAPLUS
CN 9H-Imidazo[1,2-a]purin-9-one, 3,4-dihydro-7-methyl-3-(2-C-methyl-β-D-ribofuranosyl)-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L24 ANSWER 8 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:18891 HCAPLUS
DOCUMENT NUMBER: 140:71067
TITLE: Method for preparation of large volume batches of poly-ICLC with increased biological potency, and therapeutic, clinical and veterinary uses thereof
INVENTOR(S): Salazar, Andres
PATENT ASSIGNEE(S): Oncovir, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2004005998 | A1 | 20040108 | US 2003-611614 | 20030701 |

PRIORITY APPLN. INFO.: US 2002-393713P P 20020703

AB The invention discloses a method for producing large lots of final sterile poly-ICLC suitable for clin. use with reduced toxicity at ED levels, as well as a method for using poly-ICLC to regulate genes and a method for using poly-ICLC to treat certain human and veterinary infectious, neoplastic and autoimmune disorders.

IT **59789-29-6P**, Poly-ICLC
RL: IMF (Industrial manufacture); **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of large volume batches of poly-ICLC with increased biol. potency, and therapeutic use)

RN 59789-29-6 HCAPLUS

CN L-Lysine, homopolymer, compd. with cellulose carboxymethyl ether and 5'-inosinic acid homopolymer complex with 5'-cytidylic acid homopolymer (?:?:?:1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 64769-70-6
CMF (C10 H13 N4 O8 P)x . (C9 H14 N3 O8 P)x . (C6 H14 N2 O2)x

CM 2

CRN 25104-18-1
CMF (C6 H14 N2 O2)x
CCI PMS

CM 3

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



CM 4

CRN 24939-03-5
CMF (C10 H13 N4 O8 P)x . (C9 H14 N3 O8 P)x

CM 5

CRN 30918-54-8
CMF (C10 H13 N4 O8 P)x
CCI PMS

CM 6

CRN 131-99-7
CMF C10 H13 N4 O8 P

Absolute stereochemistry.



CM 7

CRN 30811-80-4
CMF (C9 H14 N3 O8 P)x
CCI PMS

CM 8

CRN 63-37-6
CMF C9 H14 N3 O8 P

Absolute stereochemistry.



CM 9

CRN 9000-11-7
CMF C2 H4 O3 . x Unspecified

CM 10

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 11

CRN 79-14-1
CMF C2 H4 O3



L24 ANSWER 9 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:2898 HCAPLUS
DOCUMENT NUMBER: 140:42424
TITLE: Preparation of nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
INVENTOR(S): Carroll, Steven S.; Olsen, David B.; Durette, Philippe L.; Bhat, Balkrishen; Dande, Prasad; Eldrup, Anne B.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004000858 | A2 | 20031231 | WO 2003-US19172 | 20030617 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-390579P P 20020621
OTHER SOURCE(S): MARPAT 140:42424

AB The present invention provides nucleoside compds. I, wherein B is nucleobase; R1 is fluoromethyl, difluoromethyl, trifluoromethyl; R2 is H, F, amino, OH, SH, alkoxy, alkylcarbonyloxy, alkyl; R3 and R4 are independently H, Cn, N3, halogen, OH, SH, amino, alkoxy, alkylcarconyloxy, alkenyl, alkynyl; R5 is H, alkylcarbonyl, P3O9H4, P2O6H3, phosphophonyl; R6 and R7 independently H, Me, hydroxymethyl, fluoromethyl; and certain derivs. thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compds. are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compns. containing such nucleoside compds. alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compds. of the present invention. Thus, 2-amino-9-(2-C-fluoromethyl-β-D-ribofuranosyl)-3,9-dihydropurin-6-one was prepared and tested as inhibitor of RNA-dependent RNA viral polymerase. Title compds. tested in the HCV NS5B polymerase assay exhibited IC50's less than 100 μmol.

IT **636581-84-5P 636581-85-6P 636581-86-7P**
**636581-87-8P 636581-88-9P 636581-89-0P**
**636581-90-3P 636581-94-7P 636581-95-8P**
**636581-96-9P 636581-97-0P 636581-98-1P**
**636581-99-2P 636582-00-8P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nucleoside derivs. as inhibitors of RNA-dependent RNA viral polymerase)

RN 636581-84-5 HCAPLUS
CN Adenosine, 2'-C-(fluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636581-85-6 HCAPLUS
CN 9H-Purin-6-amine, 9-[2-C-(fluoromethyl)-β-D-arabinofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636581-86-7 HCAPLUS
CN Guanosine, 2'-C-(fluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636581-87-8 HCAPLUS
CN 6H-Purin-6-one, 2-amino-9-[2-C-(fluoromethyl)-β-D-arabinofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636581-88-9 HCAPLUS
CN Guanosine, 2'-C-(fluoromethyl)-6-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636581-89-0 HCAPLUS
CN Adenosine, 2-amino-2'-C-(fluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636581-90-3 HCAPLUS
CN Adenosine, 2'-C-(fluoromethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 636581-94-7 HCAPLUS
CN Adenosine 5'-(tetrahydrogen triphosphate), 2'-C-(fluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 636581-95-8 HCAPLUS
CN 9H-Purin-6-amine, 9-[2-C-(fluoromethyl)-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-arabinofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 636581-96-9 HCAPLUS
CN Guanosine 5'-(tetrahydrogen triphosphate), 2'-C-(fluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636581-97-0 HCAPLUS
CN 6H-Purin-6-one, 2-amino-9-[2-C-(fluoromethyl)-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-arabinofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636581-98-1 HCAPLUS
CN Guanosine 5'-(tetrahydrogen triphosphate), 2'-C-(fluoromethyl)-6-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636581-99-2 HCAPLUS
CN Adenosine 5'-(tetrahydrogen triphosphate), 2-amino-2'-C-(fluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636582-00-8 HCAPLUS
CN Adenosine 5'-(tetrahydrogen triphosphate), 2'-C-(fluoromethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L24 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:1006709 HCAPLUS
DOCUMENT NUMBER: 140:35898
TITLE: Carbocyclic nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
INVENTOR(S): Bhat, Balkrishen; Bhat, Neelima; Dande, Prasad; Eldrup, Anne B.; Olsen, David B.; MacCoss, Malcolm
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003105770 | A2 | 20031224 | WO 2003-US18841 | 20030614 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH,

PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-389161P P 20020617
OTHER SOURCE(S): MARPAT 140:35898

AB The present invention provides carbocyclic nucleoside compds. and certain derivs. thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compds. are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compns. containing such carbocyclic nucleoside compds. alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the carbocyclic nucleoside compds. of the present invention. HCV NS5B polymerase was inhibited with IC50's less than 100 μM.

IT **636583-01-2 636583-02-3 636583-03-4**
**636583-04-5 636583-17-0 636583-17-0D**,
pharmaceutically-acceptable salts **636583-18-1**
**636583-18-1D**, pharmaceutically-acceptable salts
**636583-19-2 636583-19-2D**, pharmaceutically-acceptable
salts **636583-20-5 636583-20-5D**, pharmaceutically-
acceptable salts
RL: BSU (Biological study, unclassified); **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study);
USES (Uses)
(carbocyclic nucleoside derivs. as inhibitors of RNA-dependent RNA viral polymerase)

RN 636583-01-2 HCAPLUS
CN 1,2-Cyclopentanediol, 5-(6-amino-9H-purin-9-yl)-3-(hydroxymethyl)-1-methyl-, (2R,3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 636583-02-3 HCAPLUS
CN 1,2-Cyclopentanediol, 5-(6-amino-9H-purin-9-yl)-3-(hydroxymethyl)-1-methyl-, (1S,2R,3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636583-03-4 HCAPLUS
CN 6H-Purin-6-one, 2-amino-9-[(1R,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)-2-methylcyclopentyl]-1,9-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636583-04-5 HCAPLUS
CN 6H-Purin-6-one, 2-amino-9-[(1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)-2-methylcyclopentyl]-1,9-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636583-17-0 HCAPLUS
CN Triphosphoric acid, P-[[(1R,2R,4R)-4-(6-amino-9H-purin-9-yl)-2,3-dihydroxy-3-methylcyclopentyl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636583-17-0 HCAPLUS
CN Triphosphoric acid, P-[[(1R,2R,4R)-4-(6-amino-9H-purin-9-yl)-2,3-dihydroxy-3-methylcyclopentyl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636583-18-1 HCAPLUS
CN Triphosphoric acid, P-[[(1R,2R,3S,4R)-4-(6-amino-9H-purin-9-yl)-2,3-dihydroxy-3-methylcyclopentyl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636583-18-1 HCAPLUS
CN Triphosphoric acid, P-[[(1R,2R,3S,4R)-4-(6-amino-9H-purin-9-yl)-2,3-dihydroxy-3-methylcyclopentyl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636583-19-2 HCAPLUS
CN Triphosphoric acid, P-[[(1R,2R,4R)-4-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-2,3-dihydroxy-3-methylcyclopentyl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636583-19-2 HCAPLUS
CN Triphosphoric acid, P-[[(1R,2R,4R)-4-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-2,3-dihydroxy-3-methylcyclopentyl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636583-20-5 HCAPLUS
CN Triphosphoric acid, P-[[(1R,2R,3S,4R)-4-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-2,3-dihydroxy-3-methylcyclopentyl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636583-20-5 HCAPLUS
CN Triphosphoric acid, P-[[(1R,2R,3S,4R)-4-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-2,3-dihydroxy-3-methylcyclopentyl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L24 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:935820 HCAPLUS
DOCUMENT NUMBER: 140:156738
TITLE: Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in Vitro
AUTHOR(S): Migliaccio, Giovanni; Tomassini, Joanne E.; Carroll, Steven S.; Tomei, Licia; Altamura, Sergio; Bhat, Balkrishen; Bartholomew, Linda; Bosserman, Michele R.; Ceccacci, Alessandra; Colwell, Lawrence F.; Cortese, Riccardo; De Francesco, Raffaele; Eldrup, Anne B.; Getty, Krista L.; Hou, Xiaoli S.; LaFemina, Robert L.; Ludmerer, Steven W.; MacCoss, Malcolm; McMasters, Daniel R.; Stahlhut, Mark W.; Olsen, David B.; Hazuda, Daria J.; Flores, Osvaldo A.
CORPORATE SOURCE: Department of Biochemistry, Istituto di Ricerche di Biologia Molecolare P. Angeletti, Pomezia, 00040, Italy
SOURCE: Journal of Biological Chemistry (2003), 278(49), 49164-49170

CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The urgent need for efficacious drugs to treat chronic hepatitis C virus (HCV) infection requires a concerted effort to develop inhibitors specific for virally encoded enzymes. We demonstrate that 2'-C-Me ribonucleosides are efficient chain-terminating inhibitors of HCV genome replication. Characterization of drug-resistant HCV replicons defined a single S282T mutation within the active site of the viral polymerase that conferred loss of sensitivity to structurally related compds. in both replicon and isolated polymerase assays. Biochem. analyses demonstrated that resistance at the level of the enzyme results from a combination of reduced affinity of the mutant polymerase for the drug and an increased ability to extend the incorporated nucleoside analog. Importantly, the combination of these agents with interferon-α results in synergistic inhibition of HCV genome replication in cell culture. Furthermore, 2'-C-methyl-substituted ribonucleosides also inhibited replication of genetically related viruses such as bovine diarrhea virus, yellow fever, and West African Nile viruses. These observations, together with the finding that 2'-C-methyl-guanosine in particular has a favorable pharmacol. profile, suggest that this class of compds. may have broad utility in the treatment of HCV and other **flavivirus** infections.

IT **374750-30-8**
RL: **DMA (Drug mechanism of action)**; **PAC (Pharmacological activity)**; **PKT (Pharmacokinetics)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro)
RN 374750-30-8 HCAPLUS
CN Guanosine, 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **15397-12-3**
RL: **DMA (Drug mechanism of action)**; **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro)
RN 15397-12-3 HCAPLUS
CN Adenosine, 2'-C-methyl- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 12 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:796878 HCAPLUS
DOCUMENT NUMBER: 139:306530
TITLE: Flt3-ligand for enhancing immune response of vaccine against cancer, allergy and infection
INVENTOR(S): Mckenna, Hilary J.; Liebowitz, David N.; Maliszewski, Charles R.
PATENT ASSIGNEE(S): Immunex Corporation, USA
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003083083 | A2 | 20031009 | WO 2003-US9773 | 20030326 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2004022760 | A1 | 20040205 | US 2003-401364 | 20030326 |

PRIORITY APPLN. INFO.: US 2002-368263P P 20020326
US 2002-427835P P 20021119

AB The present invention relates to methods of using Flt3-ligand (Flt3-L) in immunization protocols to enhance immune responses against vaccine antigens. Embodiments include administering Flt3-ligand prior to immunizing a subject with a vaccine, wherein the vaccine comprises at least one antigen formulated in one or more adjuvants. Methods of treating and preventing cancer, allergy and infection using Flt3-ligand immunization protocols are also provided. Methods of using Flt3-ligand immunization protocols for in vivo evaluation of antigens and adjuvants are also provided.

IT **24936-38-7 121288-39-9**, LOXORIBINE
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(Flt3-ligand for enhancing immune response of vaccine against cancer, allergy and infection)
RN 24936-38-7 HCAPLUS
CN 5'-Adenylic acid, homopolymer, complex with 5'-uridylic acid homopolymer (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 27416-86-0
CMF (C9 H13 N2 O9 P)x
CCI PMS

CM 2

CRN 58-97-9
CMF C9 H13 N2 O9 P

Absolute stereochemistry.




CM 3

CRN 24937-83-5
CMF (C10 H14 N5 O7 P)x
CCI PMS

CM 4

CRN 61-19-8
CMF C10 H14 N5 O7 P

Absolute stereochemistry.




RN 121288-39-9 HCAPLUS
CN Guanosine, 7,8-dihydro-8-oxo-7-(2-propenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L24 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:757325 HCAPLUS
DOCUMENT NUMBER: 139:286307
TITLE: Antimicrobial sulfated polysaccharides that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions, and methods of use
INVENTOR(S): Comper, Wayne D.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 33 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2003181416 | A1 | 20030925 | US 2002-321756 | 20021217 |
| US 2004009953 | A1 | 20040115 | US 2003-421687 | 20030423 |
| WO 2004014400 | A1 | 20040219 | WO 2003-AU488 | 20030424 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 2002-346629P P 20020110
US 2002-366532P P 20020325
US 2002-366533P P 20020325
US 2002-402695P P 20020813
US 2002-321756 A2 ~~2002~~1217

AB The invention provides methods and compns. for treating or preventing microbial infection in mammals with sulfated polysaccharides, in which the polysaccharides have a degree of sulfation effective to enable maximal interaction of constituent sulfate groups with the microbe which causes the infection, and in which the sulfated polysaccharide is not

substantially endocytosed or degraded by cell receptor binding in the mammal and thereby retains antimicrobial activity in vivo.

IT **24939-03-5**, Polyinosinic-polycytidylic acid
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(antimicrobial sulfated polysaccharides that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compns., and methods of use)

RN 24939-03-5 HCAPLUS

CN 5'-Inosinic acid, homopolymer, complex with 5'-cytidylic acid homopolymer (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 30918-54-8
CMF (C10 H13 N4 O8 P)x
CCI PMS

CM 2

CRN 131-99-7
CMF C10 H13 N4 O8 P

Absolute stereochemistry.




CM 3

CRN 30811-80-4
CMF (C9 H14 N3 O8 P)x
CCI PMS

CM 4

CRN 63-37-6
CMF C9 H14 N3 O8 P

Absolute stereochemistry.



L24 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:714459 HCAPLUS
DOCUMENT NUMBER: 140:287630
TITLE: 5'-O-Fluorosulfonylbenzoyl Esters of Purine Nucleosides as Potential Inhibitors of NTPase/Helicase and Polymerase of **Flaviviridae** Viruses
AUTHOR(S): Bretner, M.; Schalinski, S.; Borowski, P.; Kulikowski, T.
CORPORATE SOURCE: Institute of Biochemistry and Biophysics, Laboratory of Antimetabolites, Polish Academy of Sciences, Warsaw, 02-106, Pol.
SOURCE: Nucleosides, Nucleotides & Nucleic Acids (2003), 22(5-8), 1531-1533
CODEN: NNNAFY; ISSN: 1525-7770
PUBLISHER: Marcel Dekker, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Synthesis and interactions of guanosine, inosine and ribavirin 5'-fluorosulfonyl-benzoyl esters with hepatitis C virus (HCV) and **Flaviviruses** NTPase/helicase and polymerase are described.

IT **68267-13-0P 83133-70-4P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(fluorosulfonylbenzoyl esters of purine nucleosides as potential inhibitors of ntpase helicase and polymerase of **flaviviridae** viruses)

RN 68267-13-0 HCAPLUS
CN Guanosine, 5'-[4-(fluorosulfonyl)benzoate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 83133-70-4 HCAPLUS
CN Inosine, 5'-[4-(fluorosulfonyl)benzoate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:492694 HCAPLUS
DOCUMENT NUMBER: 139:47125
TITLE: Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA, and drug screening method
INVENTOR(S): Loeb, Lawrence A.; Mullins, James I.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 958,065.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| US 2003119764 | A1 | 20030626 | US 2000-522373 | | 20000310 |
| US 6063628 | A | 20000516 | US 1997-958065 | | 19971027 |
| PRIORITY APPLN. INFO.: | | | US 1996-29404P | P | 19961028 |
| | | | US 1997-40535P | P | 19970227 |
| | | | US 1997-958065 | A2 | 19971027 |

AB The present invention is directed to the identification and use of ribonucleoside analogs to induce the mutation of an RNA virus, including BVDV, HIV and HCV, or a virus which otherwise replicates through an RNA intermediate. The increase in the mutation rate of the virus results in reduced viability of progeny generations of the virus, thereby inhibiting viral replication. In addition to these methods and related compns., the invention provides methods and combinatorial chemical libraries for screening ribonucleoside analogs for mutagenic potential.

IT **58-61-7D**, Adenosine, derivs. **118-00-3D**, Guanosine, derivs. **1867-73-8 1867-73-8D**, derivs. **3868-31-3**, 8-Hydroxyguanosine **3868-31-3D**, 8-Hydroxyguanosine, derivs. **3868-32-4**, 8-Aminoguanosine **3868-32-4D**, 8-Aminoguanosine, derivs. **7803-88-5 7803-88-5D**, derivs. **39007-51-7 39007-51-7D**, derivs. **39007-52-8 39007-52-8D**, derivs. **39708-01-5 39708-01-5D**, derivs. **72055-62-0**,

3-Methyladenosine **72055-62-0D**, 3-Methyladenosine, derivs. **82773-20-4 82773-20-4D**, derivs. **108060-85-1 108060-85-1D**, derivs.
RL: BSU (Biological study, unclassified); CUS (Combinatorial use); **THU (Therapeutic use)**; BIOL (Biological study); CMBI (Combinatorial study); USES (Uses)
(induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA, and drug screening method)

RN 58-61-7 HCAPLUS
CN Adenosine (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 118-00-3 HCAPLUS
CN Guanosine (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 1867-73-8 HCAPLUS
CN Adenosine, N-methyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1867-73-8 HCAPLUS
CN Adenosine, N-methyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 3868-31-3 HCAPLUS
CN Guanosine, 7,8-dihydro-8-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 3868-31-3 HCAPLUS
CN Guanosine, 7,8-dihydro-8-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 3868-32-4 HCAPLUS
CN Guanosine, 8-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3868-32-4 HCAPLUS
CN Guanosine, 8-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 7803-88-5 HCAPLUS
CN Guanosine, 6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 7803-88-5 HCAPLUS
CN Guanosine, 6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39007-51-7 HCAPLUS
CN 3H-Imidazo[2,1-i]purine, 3-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39007-51-7 HCAPLUS
CN 3H-Imidazo[2,1-i]purine, 3-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39007-52-8 HCAPLUS
CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39007-52-8 HCAPLUS
CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39708-01-5 HCAPLUS
CN Guanosine, 6-O-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39708-01-5 HCAPLUS
CN Guanosine, 6-O-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 72055-62-0 HCAPLUS
CN Adenosine, 3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 72055-62-0 HCAPLUS
CN Adenosine, 3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82773-20-4 HCAPLUS
CN Guanosine, 6-O-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82773-20-4 HCAPLUS
CN Guanosine, 6-O-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 108060-85-1 HCAPLUS
CN 1H-Imidazo[2,1-b]purin-4(5H)-one, 1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 108060-85-1 HCAPLUS
CN 1H-Imidazo[2,1-b]purin-4(5H)-one, 1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L24 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:301196 HCAPLUS
DOCUMENT NUMBER: 138:297636
TITLE: Use of STAT-6 inhibitors as therapeutic agents
INVENTOR(S): Carson, Dennis A.; Cottam, Howard B.; Leoni, Lorenzo M.; Barchechath, Sylvie
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003031587 | A2 | 20030417 | WO 2002-US32503 | 20021009 |
| WO 2003031587 | A3 | 20040219 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2003143199 | A1 | 20030731 | US 2002-269110 | 20021009 |

PRIORITY APPLN. INFO.: US 2001-328162P P 20011009
US 2001-328689P P 20011010
OTHER SOURCE(S): MARPAT 138:297636

AB The invention provides therapeutic method to enhance the efficacy of interferon treatment comprising administering to a mammal subject to interferon treatment a compound which is an antagonist of the IL-4 or IL-13 signal transduction pathway in an amount effective to enhance said efficacy. The method includes treatment of diseases such as cancer, proliferative fibrotic diseases, viral diseases, or autoimmune diseases. The invention also includes the use of chemotherapeutic agents, radiation or other treatments in conjunction with the method of the invention.

IT **21679-14-1**, Fludarabine
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(use of STAT-6 inhibitors as therapeutic agents)
RN 21679-14-1 HCAPLUS
CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L24 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:261692 HCAPLUS
DOCUMENT NUMBER: 138:265611
TITLE: Methods and compositions for treating **flaviviruses** and pestiviruses using 4'-modified nucleosides, and preparation thereof
INVENTOR(S): Gosselin, Gilles; Imbach, Jean-Louis; Sommadossi, Jean-Pierre
PATENT ASSIGNEE(S): Idenix (Cayman) Limited, Cayman I.; Centre National de la Recherche Scientifique; L'Universite Montpellier II
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003026675 | A1 | 20030403 | WO 2002-US31203 | 20020930 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2004006002 | A1 | 20040108 | US 2002-261327 | 20020930 |

PRIORITY APPLN. INFO.: US 2001-326192P P 20010928
OTHER SOURCE(S): MARPAT 138:265611

AB A method and composition are provided for treating a host infected with **flavivirus** or pestivirus, comprising administering an effective amount of a 4'-modified nucleoside, or a pharmaceutically acceptable salt or prodrug thereof. Preparation of nucleoside derivs. is described.

IT **152540-76-6 152540-76-6D**, prodrug derivs.
**153186-32-4 153186-32-4D**, prodrug derivs.
**503543-42-8 503543-42-8D**, prodrug derivs.
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(**flavivirus** and pestivirus infection treatment using 4'-modified nucleosides, and preparation thereof)

RN 152540-76-6 HCAPLUS
CN Adenosine, 4'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152540-76-6 HCAPLUS
CN Adenosine, 4'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 153186-32-4 HCAPLUS
CN Guanosine, 4'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 153186-32-4 HCAPLUS
CN Guanosine, 4'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503543-42-8 HCAPLUS
CN Inosine, 4'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503543-42-8 HCAPLUS
CN Inosine, 4'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:173446 HCAPLUS
DOCUMENT NUMBER: 138:198576
TITLE: Mutagenic nucleoside analogs for the treatment of viral disease
INVENTOR(S): Li, Ling; Gall, Alexander; Daifuku, Richard
PATENT ASSIGNEE(S): Koronis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003018030 | A1 | 20030306 | WO 2002-US26765 | 20020821 |

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| US 2003170872 | A1 | 20030911 | US 2002-226799 | 20020821 |

PRIORITY APPLN. INFO.: US 2001-314728P P 20010824
OTHER SOURCE(S): MARPAT 138:198576

AB The present invention provides a new strategy for inhibiting viral replication. In the methods of the invention, specified deoxyribonucleoside analogs and ribonucleoside analogs are used to dramatically increase the mutation rate of the virus. This increase in the mutation rate of the virus results in reduced viability of progeny generations of the virus, thereby inhibiting viral replication.

IT **1818-71-9**, Isoguanosine **2096-10-8**, 2,6-Diaminopurine riboside
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(mutagenic nucleoside analogs for treatment of viral disease)

RN 1818-71-9 HCAPLUS
CN Adenosine, 1,2-dihydro-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 2096-10-8 HCAPLUS
CN Adenosine, 2-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:101583 HCAPLUS
DOCUMENT NUMBER: 139:46469
TITLE: Interferons, interferon inducers, and interferon-ribavirin in treatment of **flavivirus**-induced encephalitis in mice
AUTHOR(S): Leyssen, Pieter; Drosten, Christian; Paning, Marcus; Charlier, Nathalie; Paeshuyse, Jan; De Clercq, Erik; Neyts, Johan
CORPORATE SOURCE: Rega Institute for Medical Research, Katholieke Universiteit Leuven, Louvain, B-3000, Belg.
SOURCE: Antimicrobial Agents and Chemotherapy (2003), 47(2), 777-782
CODEN: AMACCQ; ISSN: 0066-4804
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We evaluated the prophylactic and therapeutic efficacy of interferon α-2b, pegylated interferon α-2b, poly(I · C), and Ampligen against Modoc virus encephalitis in an animal model for **flavivirus** infections. All compds. significantly delayed virus-induced morbidity (paralysis) and mortality (due to progressive encephalitis). Viral load (as measured on day 7 postinfection) was significantly reduced by 80 to 100% in the serum, brain, and spleen in mice that had been treated with either interferon α-2b, pegylated interferon α-2b, poly(I · C), or Ampligen. We also studied whether a combination of interferon α-2b and ribavirin (presently the standard therapy for the treatment of infections with hepatitis C virus) would be more effective than treatment with interferon alone. However, ribavirin did not enhance the inhibitory effect of interferon therapy in this animal model for **flavivirus** infections.

IT **24939-03-5**, Poly(I · C) **38640-92-5**, Ampligen
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(interferons, interferon inducers, and interferon-ribavirin in treatment of **flavivirus**-induced encephalitis)
RN 24939-03-5 HCAPLUS
CN 5'-Inosinic acid, homopolymer, complex with 5'-cytidylic acid homopolymer (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 30918-54-8

CMF (C10 H13 N4 O8 P)x
CCI PMS

CM 2

CRN 131-99-7
CMF C10 H13 N4 O8 P

Absolute stereochemistry.




CM 3

CRN 30811-80-4
CMF (C9 H14 N3 O8 P)x
CCI PMS

CM 4

CRN 63-37-6
CMF C9 H14 N3 O8 P

Absolute stereochemistry.




RN 38640-92-5 HCAPLUS
CN 5'-Inosinic acid, homopolymer, complex with 5'-cytidylic acid polymer with 5'-uridylic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 30918-54-8
CMF (C10 H13 N4 O8 P)x
CCI PMS

CM 2

CRN 131-99-7
CMF C10 H13 N4 O8 P

Absolute stereochemistry.



CM 3

CRN 26427-29-2
CMF (C9 H14 N3 O8 P . C9 H13 N2 O9 P)x
CCI PMS

CM 4

CRN 63-37-6
CMF C9 H14 N3 O8 P

Absolute stereochemistry.



CM 5

CRN 58-97-9
CMF C9 H13 N2 O9 P

Absolute stereochemistry.



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:832613 HCAPLUS
DOCUMENT NUMBER: 137:333119
TITLE: 3-Aminopyridine-2-carboxyaldehyde thiosemicarbazones and methods using them for treating viral and fungal infections
INVENTOR(S): King, Ivan C.; Doyle, Terrence W.; Sznol, Mario; Sartorelli, Alan C.; Cheng, Yung-Chi
PATENT ASSIGNEE(S): Vion Pharmaceuticals, Inc., USA; Yale University
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002085358 | A2 | 20021031 | WO 2002-US12358 | 20020418 |
| WO 2002085358 | A3 | 20021219 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| US 2002188011 | A1 | 20021212 | US 2002-126050 | 20020418 |

PRIORITY APPLN. INFO.: US 2001-285559P P 20010420
OTHER SOURCE(S): MARPAT 137:333119

AB The invention provides methods for treating viral or fungal infections using 3-aminopyridine-2-carboxyaldehyde thiosemicarbazone (3-AP) and 3-amino-4-methylpyridine-2-carboxaldehyde thiosemicarbazone (3-AMP), and prodrug forms thereof, as well as pharmaceutical compns. comprising these compds. Preparation of compds. of the invention is described.

IT **38640-92-5**, Ampligen
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(aminopyridinecarboxyaldehyde thiosemicarbazones for treatment of viral and fungal infections)

RN 38640-92-5 HCAPLUS
CN 5'-Inosinic acid, homopolymer, complex with 5'-cytidylic acid polymer with 5'-uridylic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 30918-54-8
CMF (C10 H13 N4 O8 P)x
CCI PMS

CM 2

CRN 131-99-7
CMF C10 H13 N4 O8 P

Absolute stereochemistry.



CM 3

CRN 26427-29-2
CMF (C9 H14 N3 O8 P . C9 H13 N2 O9 P)x
CCI PMS

CM 4

CRN 63-37-6
CMF C9 H14 N3 O8 P

Absolute stereochemistry.



CM 5

CRN 58-97-9
CMF C9 H13 N2 O9 P

Absolute stereochemistry.



L24 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:584808 HCAPLUS
DOCUMENT NUMBER: 137:276900
TITLE: Infection of SCID mice with Montana myotis leukoencephalitis virus as a model for **flavivirus** encephalitis
AUTHOR(S): Charlier, Nathalie; Leyssen, Pieter; Paeshuyse, Jan; Drosten, Christian; Schmitz, Herbert; Van Lommel, Alfons; De Clercq, Erik; Neyts, Johan
CORPORATE SOURCE: Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Louvain, B-3000, Belg.
SOURCE: Journal of General Virology (2002), 83(8), 1887-1896
CODEN: JGVIAY; ISSN: 0022-1317
PUBLISHER: Society for General Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB We have established a convenient animal model for **flavivirus** encephalitis using Montana Myotis leukoencephalitis virus (MMLV), a bat **flavivirus**. This virus has the same genomic organization, and contains the same conserved motifs in genes that encode potential antiviral targets, as **flaviviruses** that cause disease in man (Charlier, N., et al., 2002), and has a similar particle size (approx. 40 nm). MMLV replicates well in Vero cells and appears to be equally as sensitive as yellow fever virus and dengue fever virus to a selection of exptl. antiviral agents. Cells infected with MMLV show dilation of the endoplasmic reticulum, a characteristic of **flavivirus** infection. I.p., intranasal or direct intracerebral inoculation of SCID mice with MMLV resulted in encephalitis ultimately leading to death, whereas immunocompetent mice were refractory to either intranasal or i.p. infection with MMLV. Viral RNA and/or antigens were detected in the brain and serum of MMLV-infected SCID mice, but not in any other organ examined: MMLV was detected in the olfactory lobes, the cerebral cortex, the limbic structures, the midbrain, cerebellum and medulla oblongata. Infection was confined to neurons. Treatment with the interferon-α/β inducer poly(I)·poly(C) protected SCID mice against MMLV-induced morbidity and mortality, and this protection correlated with a reduction in infectious virus titer and viral RNA load. This validates the MMLV model for use in antiviral drug studies. The MMLV SCID model may, therefore, be attractive for the study of chemoprophylactic or chemotherapeutic strategies against **flavivirus** infections causing encephalitis.
IT **24939-03-5**, Poly(I)·poly(C)
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(infection of SCID mice with Montana myotis leukoencephalitis virus as model for **flavivirus** encephalitis)
RN 24939-03-5 HCAPLUS
CN 5'-Inosinic acid, homopolymer, complex with 5'-cytidylic acid homopolymer (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 30918-54-8
CMF (C10 H13 N4 O8 P)x
CCI PMS

CM 2

CRN 131-99-7
CMF C10 H13 N4 O8 P

Absolute stereochemistry.



CM 3

CRN 30811-80-4
CMF (C9 H14 N3 O8 P)x
CCI PMS

CM 4

CRN 63-37-6
CMF C9 H14 N3 O8 P

Absolute stereochemistry.



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:521462 HCAPLUS
DOCUMENT NUMBER: 137:88442
TITLE: Incensole and furanogermacrens and compounds in treatment for inhibiting neoplastic lesions and microorganisms
INVENTOR(S): Shanahan-Pendergast, Elisabeth
PATENT ASSIGNEE(S): Ire.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

WO 2002053138 A2 20020711 WO 2002-IE1 20020102
WO 2002053138 A3 20020919
W: AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG
EP 1351678 A2 20031015 EP 2002-727007 20020102
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2004092583 A1 20040513 US 2004-250535 20040102
PRIORITY APPLN. INFO.: IE 2001-2 A 20010102
WO 2002-IE1 W 20020102
OTHER SOURCE(S): MARPAT 137:88442

AB The invention discloses the use of incensole and/or furanogermacrens, derivs. metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immundysregulatory disorders. These compds. can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacren and their mixture showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.

IT **5536-17-4**, Vidarabine **29984-33-6**, Vidarabine Phosphate **51867-87-9 110143-10-7**, Lodenosine
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(pharmaceutical formulation further containing; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

RN 5536-17-4 HCAPLUS
CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 29984-33-6 HCAPLUS
CN 9H-Purin-6-amine, 9-(5-O-phosphono-β-D-arabinofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51867-87-9 HCAPLUS
CN 9H-Purin-6-amine, 9-(5-O-phosphono-β-D-arabinofuranosyl)-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 110143-10-7 HCAPLUS
CN 9H-Purin-6-amine, 9-(2,3-dideoxy-2-fluoro-β-D-threo-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **53-79-2**, Puromycin **58-58-2**, Puromycin Hydrochloride **7724-76-7**, Riboprine **21679-14-1**, Fludarabine **75607-67-9**, Fludarabine Phosphate **121288-39-9**, Loxoribine

RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

RN 53-79-2 HCAPLUS
CN Adenosine, 3'-[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3'-deoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 58-58-2 HCAPLUS
CN Adenosine, 3'-[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3'-deoxy-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 7724-76-7 HCAPLUS
CN Adenosine, N-(3-methyl-2-butenyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 21679-14-1 HCAPLUS
CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 75607-67-9 HCAPLUS
CN 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-β-D-arabinofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 121288-39-9 HCAPLUS
CN Guanosine, 7,8-dihydro-8-oxo-7-(2-propenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L24 ANSWER 23 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:466023 HCAPLUS
DOCUMENT NUMBER: 137:41715
TITLE: Nucleotide derivatives and mycophenolic acid derivatives as antiviral agents for treatment of **Flaviviridae** infections and abnormal cellular proliferation, and preparation thereof
INVENTOR(S): Stuyver, Lieven; Pankiewicz, Krysztof W.; Patterson, Steven; Otto, Michael J.; Watanabe, Kyoichi A.
PATENT ASSIGNEE(S): Pharmasset Ltd., USA
SOURCE: PCT Int. Appl., 165 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002048165 | A2 | 20020620 | WO 2001-US49231 | 20011217 |
| WO 2002048165 | A3 | 20030501 | | |
| WO 2002048165 | C1 | 20031211 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| AU 2002032660 | A5 | 20020624 | AU 2002-32660 | 20011217 |
| EP 1366055 | A2 | 20031203 | EP 2001-992193 | 20011217 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | US 2000-256066P | P | 20001215 |
| | WO 2001-US49231 | W | 20011217 |

OTHER SOURCE(S): MARPAT 137:41715

AB The invention discloses a composition for and a method of treating **Flaviviridae** (Hepacivirus, **Flavivirus**, Pestivirus) infections, including BVDV and HCV, in a host, including animals, and especially humans, using a nucleotide derivative or mycophenolic acid derivative or pharmaceutically acceptable salt or prodrug thereof. Methods using the compds. of the invention for the treatment of abnormal cellular

proliferation are also disclosed.

IT **83285-83-0 83285-83-0D**, derivs. **102977-57-1 102977-57-1D**, derivs. **156724-91-3 156724-91-3D**, derivs. **162870-11-3 162870-11-3D**, derivs. **188413-10-7 188413-10-7D**, derivs. **192137-89-6 192137-89-6D**, derivs. **206540-15-0 206540-68-3 206540-68-3D**, derivs. **244242-36-2 244242-36-2D**, derivs. **437999-71-8 437999-71-8D**, derivs. **437999-72-9 437999-72-9D**, derivs. **437999-73-0 437999-73-0D**, derivs. **437999-74-1 437999-74-1D**, derivs. **437999-75-2 437999-75-2D**, derivs. **437999-76-3 437999-76-3D**, derivs.
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(antiviral agents for treatment of **Flaviviridae** infections and abnormal cellular proliferation)

RN 83285-83-0 HCAPLUS

CN Adenosine 5'-(trihydrogen diphosphate), P'→5'-ester with 2-β-D-ribofuranosyl-4-thiazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 83285-83-0 HCAPLUS

CN Adenosine 5'-(trihydrogen diphosphate), P'→5'-ester with 2-β-D-ribofuranosyl-4-thiazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 102977-57-1 HCAPLUS
CN Adenosine, 5'-[hydrogen (phosphonomethyl)phosphonate], P'→5'-ester with 2-β-D-ribofuranosyl-4-thiazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 102977-57-1 HCAPLUS
CN Adenosine, 5'-[hydrogen (phosphonomethyl)phosphonate], P'→5'-ester with 2-β-D-ribofuranosyl-4-thiazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 156724-91-3 HCAPLUS
CN Adenosine 5'-(trihydrogen diphosphate), P'→5'-ester with 3-β-D-ribofuranosylbenzamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 156724-91-3 HCAPLUS
CN Adenosine 5'-(trihydrogen diphosphate), P'→5'-ester with 3-β-D-ribofuranosylbenzamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 162870-11-3 HCAPLUS
CN 4-Thiazolecarboxamide, 2-[5-O-[hydroxy(phosphonooxy)phosphinyl]-β-D-ribofuranosyl]-, P'→5'-ester with 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 162870-11-3 HCAPLUS
CN 4-Thiazolecarboxamide, 2-[5-O-[hydroxy(phosphonooxy)phosphinyl]-β-D-ribofuranosyl]-, P'→5'-ester with 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—$NH_2$

RN 188413-10-7 HCAPLUS
CN Adenosine, 5'-[hydrogen (phosphonomethyl)phosphonate], P'→5'-ester with 3-β-D-ribofuranosylbenzamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—$NH_2$

RN 188413-10-7 HCAPLUS
CN Adenosine, 5'-[hydrogen (phosphonomethyl)phosphonate], P'→5'-ester with 3-β-D-ribofuranosylbenzamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 192137-89-6 HCAPLUS
CN Adenosine, 5'-[hydrogen (difluorophosphonomethyl)phosphonate], P'→5'-ester with 2-β-D-ribofuranosyl-4-thiazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 192137-89-6 HCAPLUS
CN Adenosine, 5'-[hydrogen (difluorophosphonomethyl)phosphonate], P'→5'-ester with 2-β-D-ribofuranosyl-4-thiazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 206540-15-0 HCAPLUS
CN Benzamide, 3-[5-O-[hydroxy(phosphonomethyl)phosphinyl]-β-D-ribofuranosyl]-, P'→5'-ester with 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 206540-68-3 HCAPLUS
CN Adenosine, 5'-[hydrogen (difluorophosphonomethyl)phosphonate], P'→5'-ester with 3-β-D-ribofuranosylbenzamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 206540-68-3 HCAPLUS
CN Adenosine, 5'-[hydrogen (difluorophosphonomethyl)phosphonate], P'→5'-ester with 3-β-D-ribofuranosylbenzamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 244242-36-2 HCAPLUS
CN Adenosine, 5'-[hydrogen [[[2-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-

oxo-5-isobenzofuranyl)ethoxy]hydroxyphosphinyl]methyl]phosphonate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 244242-36-2 HCAPLUS
CN Adenosine, 5'-[hydrogen [[[2-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)ethoxy]hydroxyphosphinyl]methyl]phosphonate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 437999-71-8 HCAPLUS
CN Adenosine, 5'-ester with thiodiphosphoric acid ([(HO)2P(O)]2S), P'→5'-ester with 3-β-D-ribofuranosylbenzamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 437999-71-8 HCAPLUS
CN Adenosine, 5'-ester with thiodiphosphoric acid ([(HO)2P(O)]2S), P'→5'-ester with 3-β-D-ribofuranosylbenzamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 437999-72-9 HCAPLUS
CN Adenosine, 5'-[hydrogen (fluorophosphonomethyl)phosphonate], P'→5'-ester with 3-β-D-ribofuranosylbenzamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—$NH_2$

RN 437999-72-9 HCAPLUS
CN Adenosine, 5'-[hydrogen (fluorophosphonomethyl)phosphonate], P'→5'-ester with 3-β-D-ribofuranosylbenzamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—$NH_2$

RN 437999-73-0 HCAPLUS

CN Adenosine, 5'-ester with thiodiphosphoric acid ([(HO)2P(O)]2S), P'→5'-ester with 2-β-D-ribofuranosyl-4-thiazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—NH2

RN 437999-73-0 HCAPLUS
CN Adenosine, 5'-ester with thiodiphosphoric acid ([(HO)2P(O)]2S), P'→5'-ester with 2-β-D-ribofuranosyl-4-thiazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—NH2

RN 437999-74-1 HCAPLUS
CN Adenosine, 5'-[hydrogen (fluorophosphonomethyl)phosphonate],

P'→5'-ester with 2-β-D-ribofuranosyl-4-thiazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 437999-74-1 HCAPLUS
CN Adenosine, 5'-[hydrogen (fluorophosphonomethyl)phosphonate], P'→5'-ester with 2-β-D-ribofuranosyl-4-thiazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 437999-75-2 HCAPLUS
CN Adenosine, 2-amino-, 5'-[hydrogen (phosphonomethyl)phosphonate], P'→5'-ester with 3-β-D-ribofuranosylbenzamide (9CI) (CA INDEX

NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 437999-75-2 HCAPLUS
CN Adenosine, 2-amino-, 5'-[hydrogen (phosphonomethyl)phosphonate], P'→5'-ester with 3-β-D-ribofuranosylbenzamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 437999-76-3 HCAPLUS
CN Adenosine, 5'-[hydrogen [[[[4-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-2-methyl-2-butenyl]oxy]hydroxyphosphinyl]methyl]phosphonate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



RN 437999-76-3 HCAPLUS
CN Adenosine, 5'-[hydrogen [[[[4-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-2-methyl-2-butenyl]oxy]hydroxyphosphinyl]methyl]phosphonate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A




PAGE 1-B




L24 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:458415 HCAPLUS
DOCUMENT NUMBER: 138:100377
TITLE: Identification of active antiviral compounds against a New York isolate of West Nile virus
AUTHOR(S): Morrey, John D.; Smee, Donald F.; Sidwell, Robert W.; Tseng, Christopher
CORPORATE SOURCE: Department of Animal, Dairy, and Veterinary Sciences, Institute for Antiviral Research, Utah State University, Logan, UT, 84322-4700, USA
SOURCE: Antiviral Research (2002), 55(1), 107-116
CODEN: ARSRDR; ISSN: 0166-3542
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The recent West Nile virus (WNV) outbreak in the United States has increased the need to identify effective therapies for this disease. A chemotherapeutic approach may be a reasonable strategy because the virus infection is typically not chronic and antiviral drugs have been identified to be effective in vitro against other **flaviviruses**. A panel of 34 substances was tested against infection of a recent New York isolate of WNV in Vero cells and active compds. were also evaluated in MA-104 cells. Some of these compds. were also evaluated in Vero cells against the 1937 Uganda isolate of the WNV. Six compds. were identified to be effective against virus-induced CPE with 50% effective concns. (EC50) less than 10 μg/mL and with a selectivity index (SI) of greater than 10. Known inhibitors of orotidine monophosphate decarboxylase and inosine monophosphate dehydrogenase involved in the synthesis of GTP, UTP, and TTP were most effective. The compds. 6-azauridine, 6-azauridine triacetate, cyclopententylcytosine (CPE-C), mycophenolic acid and pyrazofurin appeared to have the greatest activities against the New York

isolate, followed by 2-thio-6-azauridine. Anti-WNV activity of 6-azauridine was confirmed by virus yield reduction assay when the assay was performed 2 days after initial infection in Vero cells. The neutral red assay mean EC50 of ribavirin was only 106 μg/mL with a mean SI of 9.4 against the New York isolate and only slightly more effective against the Uganda isolate. There were some differences in the drug sensitivities of the New York and Uganda isolates, but when comparisons were made by categorizing drugs according to their modes of action, similarities of activities between the two isolates were identified.

IT **102977-57-1**
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(identification of active antiviral compds. against a New York isolate of West Nile virus)

RN 102977-57-1 HCAPLUS

CN Adenosine, 5'-[hydrogen (phosphonomethyl)phosphonate], P'→5'-ester with 2-β-D-ribofuranosyl-4-thiazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—NH2

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 25 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:314958 HCAPLUS
DOCUMENT NUMBER: 136:340939
TITLE: Preparation of modified nucleosides for treatment of viral infections and abnormal cellular proliferation
INVENTOR(S): Stuyver, Lieven; Watanabe, Kyoichi A.
PATENT ASSIGNEE(S): Pharmasset Limited, USA
SOURCE: PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002032920 | A2 | 20020425 | WO 2001-US46113 | 20011018 |
| WO 2002032920 | A3 | 20040219 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| AU 2002028749 | A5 | 20020429 | AU 2002-28749 | 20011018 |
| US 2003087873 | A1 | 20030508 | US 2001-45292 | 20011018 |
| EP 1411954 | A2 | 20040428 | EP 2001-987756 | 20011018 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | US 2000-241488P | P | 20001018 |
| | US 2001-282156P | P | 20010406 |
| | WO 2001-US46113 | W | 20011018 |

OTHER SOURCE(S): MARPAT 136:340939

AB Modified nucleosides, e.g. I, wherein D is hydrogen, alkyl, acyl, monophosphate, diphosphate, triphosphate, monophosphate ester, diphosphate ester, triphosphate ester, phospholipid or amino acid; X is H, halogen, NH2, substituted amine, oxime, OH, alkoxy, SH, thioalkyl; Y is O, S, Se; R and R1 are independently H, alkyl, alkenyl, alkynyl, aryl, alkylaryl, halogen, NH2, substituted amine, oxime, hydrazine, OH, alkoxy, SH, thioalkyl, NO2, NO, CH2OH, CH2OH, ester, CONH2, amide, CN; R2 and R3 are independently H, halogen, OH, SH, OMe, SMe, NH2, NHMe, CH:CH2, CN, CH2NH2, CH2OH, CO2H; were prepared for treating a **Flaviviridae** (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction ("TR-PCR"). Addnl., the invention discloses probe mols. that can fluoresce proportionally to the amount of virus present in a sample. Thus, (1'R,2'S,3'R,4'R)-1-[2,3-dihydroxy-4-(hydroxymethyl)cyclopentan-1-yl]-5-fluorocytosine was prepared and tested in vitro as antiviral and antitumor agent.

IT **73-03-0P 2096-10-8P 3080-29-3P**
**5399-87-1P 6982-08-7P 42867-78-7P**
**75059-22-2P 100570-76-1P 103884-98-6P**
**132722-95-3P 170157-95-6P 193754-19-7P**
**210474-57-0P 221617-05-6P 405238-72-4P**
**405238-74-6P 415705-27-0P 415705-29-2P**
**415705-30-5P 415705-31-6P 415705-32-7P**
**415705-33-8P 415705-84-9P**
RL: IMF (Industrial manufacture); **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of modified nucleosides for treatment of viral infections and abnormal cellular proliferation)

RN 73-03-0 HCAPLUS
CN Adenosine, 3'-deoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 2096-10-8 HCAPLUS
CN Adenosine, 2-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3080-29-3 HCAPLUS
CN 9H-Purin-6-amine, 9-β-L-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 5399-87-1 HCAPLUS
CN 9H-Purine, 6-chloro-9-β-D-ribofuranosyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 6982-08-7 HCAPLUS
CN 9H-Purine, 6-chloro-9-(3-deoxy-β-D-erythro-pentofuranosyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 42867-78-7 HCAPLUS
CN 9H-Purin-6-amine, 9-(2-O-acetyl-3-bromo-3-deoxy-β-D-xylofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 75059-22-2 HCAPLUS
CN Adenosine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 100570-76-1 HCAPLUS
CN 9H-Purin-2-amine, 6,6'-dithiobis[9-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A



PAGE 2-A

RN 103884-98-6 HCAPLUS
CN 6H-Purin-6-one, 2-amino-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-1,9-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 132722-95-3 HCAPLUS
CN 9H-Purine, 6-chloro-9-(2,3-dideoxy-2-fluoro-β-D-threo-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170157-95-6 HCAPLUS
CN 9H-Purin-6-amine, 9-(3-deoxy-β-L-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 193754-19-7 HCAPLUS
CN 6H-Purin-6-one, 2-amino-9-(2-deoxy-2-fluoro-β-L-arabinofuranosyl)-1,9-

dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 210474-57-0 HCAPLUS
CN 2-Furanmethanol, 5-(6-chloro-9H-purin-9-yl)-4-fluoro-2,5-dihydro-, (2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 221617-05-6 HCAPLUS
CN 2-Furanmethanol, 5-(6-amino-2-fluoro-9H-purin-9-yl)-4-fluoro-2,5-dihydro-, (2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 405238-72-4 HCAPLUS
CN 2-Furanmethanol, 5-(6-chloro-9H-purin-9-yl)-4-fluoro-2,5-dihydro-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 405238-74-6 HCAPLUS
CN 2-Furanmethanol, 5-(6-amino-2-fluoro-9H-purin-9-yl)-4-fluoro-2,5-dihydro-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 415705-27-0 HCAPLUS
CN 9H-Purin-6-amine, 9-(3-deoxy-3-fluoro-β-L-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 415705-29-2 HCAPLUS
CN 9H-Purine, 6-chloro-9-(2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 415705-30-5 HCAPLUS
CN 9H-Purine, 6-chloro-9-(2,3-di-O-acetyl-β-D-ribofuranosyl)-2-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 415705-31-6 HCAPLUS
CN 9H-Purine, 6-chloro-9-(2,3-di-O-acetyl-β-L-ribofuranosyl)-2-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 415705-32-7 HCAPLUS
CN 9H-Purine, 6-chloro-9-β-L-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 415705-33-8 HCAPLUS
CN 9H-Purine, 6-chloro-9-(3-deoxy-β-L-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 415705-84-9 HCAPLUS
CN 9H-Purin-2-amine, 6,6'-dithiobis[9-β-L-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




L24 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:293473 HCAPLUS
DOCUMENT NUMBER: 136:308528
TITLE: Vaccine compositions comprise Yershinia adhesion protein as adjuvant
INVENTOR(S): Hermand, Philippe; Vande Velde, Vincent
PATENT ASSIGNEE(S): Smithkline Beecham Biologicals SA, Belg.
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002030458 | A1 | 20020418 | WO 2001-EP3786 | 20010326 |
| WO 2002030458 | C1 | 20020718 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001062163 A5 20020422 AU 2001-62163 20010326
PRIORITY APPLN. INFO.: GB 2000-25058 A 20001012
WO 2001-EP3786 W 20010326

AB The present invention relates to adjuvant compns. which are suitable to be used in vaccines. In particular, the adjuvant compns. of the present invention comprises a Yersinia adhesion protein, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.

IT **2382-65-2**
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(oligonucleotides containing; vaccine compns. comprise Yershinia adhesion protein as adjuvant)

RN 2382-65-2 HCAPLUS
CN Guanosine, cytidylyl-(3'→5')- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:886155 HCAPLUS
DOCUMENT NUMBER: 136:590
TITLE: Methods and compositions using modified nucleosides for treating **flaviviruses** and pestiviruses
INVENTOR(S): Sommadossi, Jean-Pierre; Lacolla, Paolo
PATENT ASSIGNEE(S): Novirio Pharmaceuticals Limited, Cayman I.; Universita Degli Studi Di Cagliari
SOURCE: PCT Int. Appl., 302 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001092282 | A2 | 20011206 | WO 2001-US16687 | 20010523 |
| WO 2001092282 | A3 | 20020502 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| EP 1294735 | A2 | 20030326 | EP 2001-952131 | 20010523 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

| | | | | |
|---|---|---|---|---|
| US 2003060400 | A1 | 20030327 | US 2001-863816 | 20010523 |
| JP 2004510698 | T2 | 20040408 | JP 2002-500895 | 20010523 |
| NO 2002005600 | A | 20030117 | NO 2002-5600 | 20021121 |
| US 2004063622 | A1 | 20040401 | US 2003-602693 | 20030620 |
| US 2004097462 | A1 | 20040520 | US 2003-602692 | 20030620 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 2000-207674P | P | 20000526 |
| US 2001-283276P | P | 20010411 |
| US 2001-863816 | A3 | 20010523 |
| WO 2001-US16687 | W | 20010523 |

OTHER SOURCE(S): MARPAT 136:590

AB A method and composition are provided for treating a host infected with **flavivirus** or pestivirus, comprising administering an effective amount of a 1', 2' or 3'-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof.

IT **15397-12-3 16848-12-7 374750-30-8 374750-32-0**
RL: ADV (Adverse effect, including toxicity); **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(nucleoside derivs. for treating **flaviviruses** and pestiviruses)

RN 15397-12-3 HCAPLUS
CN Adenosine, 2'-C-methyl- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 16848-12-7 HCAPLUS
CN Adenosine, 1'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 374750-30-8 HCAPLUS
CN Guanosine, 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 374750-32-0 HCAPLUS
CN Inosine, 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **374750-27-3 374750-29-5**
RL: BSU (Biological study, unclassified); **PKT (Pharmacokinetics)** ; BIOL (Biological study)
(nucleoside derivs. for treating **flaviviruses** and pestiviruses)
RN 374750-27-3 HCAPLUS
CN Adenosine 5'-(tetrahydrogen triphosphate), 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 374750-29-5 HCAPLUS
CN Guanosine 5'-(tetrahydrogen triphosphate), 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **54401-19-3 374750-31-9**
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(nucleoside derivs. for treating **flaviviruses** and pestiviruses)
RN 54401-19-3 HCAPLUS
CN Guanosine, 1'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 374750-31-9 HCAPLUS

CN Inosine, 1'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L24 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:617773 HCAPLUS
DOCUMENT NUMBER: 135:175346
TITLE: Method for the treatment or prevention of **flavivirus** infections using nucleoside analogues
INVENTOR(S): Ismaili, Hicham Moulay Alaoui; Cheng, Yun-Xing; Lavallee, Jean-Francois; Siddiqui, Arshad; Storer, Richard
PATENT ASSIGNEE(S): Biochem Pharma Inc., Can.
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001060315 | A2 | 20010823 | WO 2001-CA197 | 20010219 |
| WO 2001060315 | A3 | 20030116 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2001035278 | A5 | 20010827 | AU 2001-35278 | 20010219 |
| EP 1296690 | A2 | 20030402 | EP 2001-907276 | 20010219 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2003523978 | T2 | 20030812 | JP 2001-559414 | 20010219 |
| US 2002019363 | A1 | 20020214 | US 2001-785235 | 20010220 |
| NO 2002003884 | A | 20021017 | NO 2002-3884 | 20020816 |

PRIORITY APPLN. INFO.: US 2000-183349P P 20000218
WO 2001-CA197 W 20010219
OTHER SOURCE(S): MARPAT 135:175346
AB The present invention relates to a method for the treatment or prevention

of **Flavivirus** infections using nucleoside analogs in a host comprising administering a therapeutically effective amount of the nucleoside analog or a pharmaceutically acceptable salt thereof.

IT **2004-07-1 3608-58-0**, 3'-Deoxyguanosine
**27462-39-1 55968-37-1**, 3'-Deoxyguanosine-5'-triphosphate
**123402-21-1 123402-27-7 141320-63-0**
**355805-44-6 355805-45-7 355805-55-9**
**355805-62-8 355805-63-9 355805-64-0**
**355805-72-0**
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(method for treatment or prevention of **flavivirus** infections using nucleoside analogs and their combination with other agents in relation to hepatitis C virus RNA-dependent RNA polymerase (NS5B protein))

RN 2004-07-1 HCAPLUS
CN 9H-Purin-2-amine, 6-chloro-9-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 3608-58-0 HCAPLUS
CN Guanosine, 3'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 27462-39-1 HCAPLUS
CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-β-D-xylofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 55968-37-1 HCAPLUS
CN Guanosine 5'-(tetrahydrogen triphosphate), 3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123402-21-1 HCAPLUS
CN Guanosine, 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123402-27-7 HCAPLUS
CN Guanosine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141320-63-0 HCAPLUS
CN Guanosine, 3'-deoxy-3'-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355805-44-6 HCAPLUS
CN Guanosine, N-acetyl-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355805-45-7 HCAPLUS
CN Guanosine 5'-(tetrahydrogen triphosphate), N-acetyl-3'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355805-55-9 HCAPLUS
CN 9H-Purin-2-amine, 6-chloro-9-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355805-62-8 HCAPLUS
CN Guanosine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355805-63-9 HCAPLUS
CN Guanosine, 3'-deoxy-3'-(difluoromethylene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355805-64-0 HCAPLUS
CN Guanosine 5'-(tetrahydrogen triphosphate), 3'-deoxy-3'-(difluoromethylene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355805-72-0 HCAPLUS
CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[5-O-[hydroxy[[hydroxy(phosphonooxy) phosphinyl]oxy]phosphinyl]-β-D-xylofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L24 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:300514 HCAPLUS
DOCUMENT NUMBER: 134:331617
TITLE: Oil-in-water emulsion compositions for polyfunctional active ingredients
INVENTOR(S): Chen, Feng-jing; Patel, Mahesh V.

PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001028555 | A1 | 20010426 | WO 2000-US28835 | 20001018 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2002107265 | A1 | 20020808 | US 1999-420159 | 19991018 |
| US 6720001 | B2 | 20040413 | | |

PRIORITY APPLN. INFO.: US 1999-420159 A 19991018

AB Pharmaceutical oil-in-water emulsions for delivery of polyfunctional active ingredients with improved loading capacity, enhanced stability, and reduced irritation and local toxicity are described. Emulsions include an aqueous phase, an oil phase comprising a structured triglyceride, and an emulsifier. The structured triglyceride of the oil phase is substantially free of triglycerides having three medium chain (C6-C12) fatty acid moieties, or a combination of a long chain triglyceride and a polarity-enhancing polarity modifier. The present invention also provides methods of treating an animal with a polyfunctional active ingredient, using dosage forms of the pharmaceutical emulsions. For example, an emulsion was prepared, with cyclosporin A as the polyfunctional active ingredient dissolved in an oil phase including a structured triglyceride (Captex 810D) and a long chain triglyceride (safflower oil). The composition contained (by weight) cyclosporin A 1.0, Captex 810D 5.0, safflower oil 5.0, BHT 0.02, egg phospholipid 2.4, dimyristoylphosphatidyl glycerol 0.2, glycerol 2.25, EDTA 0.01, and water up to 100%, resp.

IT **21679-14-1**, Fludarabine
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(oil-in-water emulsion compns. for polyfunctional active ingredients)

RN 21679-14-1 HCAPLUS
CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:136991 HCAPLUS
DOCUMENT NUMBER: 134:198075
TITLE: Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
INVENTOR(S): Patel, Mahesh V.; Chen, Feng-Jing
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001012155 | A1 | 20010222 | WO 2000-US18807 | 20000710 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 6309663 | B1 | 20011030 | US 1999-375636 | 19990817 |
| EP 1210063 | A1 | 20020605 | EP 2000-947184 | 20000710 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| JP 2003506476 | T2 | 20030218 | JP 2001-516502 | 20000710 |
| US 2001024658 | A1 | 20010927 | US 2000-751968 | 20001229 |
| US 6458383 | B2 | 20021001 | | |

PRIORITY APPLN. INFO.: US 1999-375636 A 19990817
WO 2000-US18807 W 20000710

AB The present invention relates to triglyceride-free pharmaceutical compns., pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. The compns. and systems include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the composition, or can be co-administered with the composition as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compns. and systems. For example, when a composition containing Cremophor RH40 0.30, Arlacel 186 0.20, Na taurocholate 0.18, and propylene glycol 0.32 g, resp., was used, the relative absorption of PEG 4000 as a model macromol. drug was enhanced by 991%.

IT **53-79-2**, Puromycin **21679-14-1**, Fludarabine
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

RN 53-79-2 HCAPLUS
CN Adenosine, 3'-[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3'-deoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 21679-14-1 HCAPLUS
CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:16333 HCAPLUS
DOCUMENT NUMBER: 134:246909
TITLE: A Novel Model for the Study of the Therapy of **Flavivirus** Infections Using the Modoc Virus
AUTHOR(S): Leyssen, Pieter; Van Lommel, Alfons; Drosten, Christian; Schmitz, Herbert; De Clercq, Erik; Neyts, Johan
CORPORATE SOURCE: Rega Institute for Medical Research, Katholieke Universiteit Leuven, Louvain, B-3000, Belg.
SOURCE: Virology (2001), 279(1), 27-37
CODEN: VIRLAX; ISSN: 0042-6822
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The murine **Flavivirus** Modoc replicates well in Vero cells and appears to be as equally sensitive as both yellow fever and dengue fever virus to a selection of antiviral agents. Infection of SCID mice, by either the intracerebral, i.p., or intranasal route, results in 100% mortality. Immunocompetent mice and hamsters proved to be susceptible to the virus only when inoculated via the intranasal or intracerebral route. Animals ultimately die of (histol. proven) encephalitis with features

similar to **Flavivirus** encephalitis in man. Viral RNA was detected in the brain, spleen, and salivary glands of infected SCID mice and the brain, lung, kidney, and salivary glands of infected hamsters. In SCID mice, the interferon inducer poly IC protected against Modoc virus-induced morbidity and mortality and this protection was associated with a reduction in infectious virus content and viral RNA load. Infected hamsters shed the virus in the urine. This allows daily monitoring of (inhibition of) viral replication, by means of a noninvasive method and in the same animal. The Modoc virus model appears attractive for the study of chemoprophylactic or chemotherapeutic strategies against **Flavivirus** infections. (c) 2001 Academic Press.

IT **24939-03-5**, Poly IC
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(model for study of therapy of **flavivirus** infections using Modoc virus)

RN 24939-03-5 HCAPLUS

CN 5'-Inosinic acid, homopolymer, complex with 5'-cytidylic acid homopolymer (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 30918-54-8
CMF (C10 H13 N4 O8 P)x
CCI PMS

CM 2

CRN 131-99-7
CMF C10 H13 N4 O8 P

Absolute stereochemistry.




CM 3

CRN 30811-80-4
CMF (C9 H14 N3 O8 P)x
CCI PMS

CM 4

CRN 63-37-6
CMF C9 H14 N3 O8 P

Absolute stereochemistry.




REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:756545 HCAPLUS
DOCUMENT NUMBER: 133:340220
TITLE: Adjuvant comprising a saponin and an immunostimulatory oligonucleotide for manufacture of vaccines
INVENTOR(S): Friede, Martin; Garcon, Nathalie; Hermand, Philippe
PATENT ASSIGNEE(S): Smithkline Beecham Biologicals SA, Belg.
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000062800 | A2 | 20001026 | WO 2000-EP2920 | 20000404 |
| WO 2000062800 | A3 | 20010111 | | |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 6558670 | B1 | 20030506 | US 1999-301829 | 19990429 |
| BR 2000010612 | A | 20020213 | BR 2000-10612 | 20000404 |
| TR 200103018 | T2 | 20020221 | TR 2001-200103018 | 20000404 |
| EP 1187629 | A2 | 20020320 | EP 2000-920647 | 20000404 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| JP 2002542203 | T2 | 20021210 | JP 2000-611936 | 20000404 |
| AU 764969 | B2 | 20030904 | AU 2000-41149 | 20000404 |
| US 6544518 | B1 | 20030408 | US 2000-690921 | 20001018 |
| NO 2001005073 | A | 20011122 | NO 2001-5073 | 20011018 |
| ZA 2001008619 | A | 20020912 | ZA 2001-8619 | 20011019 |
| US 2003161834 | A1 | 20030828 | US 2003-379164 | 20030303 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| GB 1999-8885 | A | 19990419 |
| US 1999-301829 | A | 19990429 |
| WO 2000-EP2920 | W | 20000404 |
| US 2000-690921 | A3 | 20001018 |

AB The present invention relates to adjuvant compns. which are suitable to be

used in vaccines. In particular, the adjuvant compns. of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.

IT **2382-65-2**
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(adjuvant comprising a saponin and an immunostimulatory oligonucleotide for manufacture of vaccines)

RN 2382-65-2 HCAPLUS
CN Guanosine, cytidylyl-(3'→5')- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



L24 ANSWER 33 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:608598 HCAPLUS
DOCUMENT NUMBER: 133:187940
TITLE: Synergistic combination for treatment of viral-mediated diseases
INVENTOR(S): Tan, Yin Hwee; Driscoll, John S.
PATENT ASSIGNEE(S): Institute of Molecular and Cell Biology, Singapore
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000050064 | A2 | 20000831 | WO 2000-US4699 | 20000225 |
| WO 2000050064 | A3 | 20010405 | | |

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,

CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1154787 A2 20011121 EP 2000-913596 20000225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
PRIORITY APPLN. INFO.: US 1999-121931P P 19990226
US 2000-181068P P 20000208
WO 2000-US4699 W 20000225
OTHER SOURCE(S): MARPAT 133:187940
AB **Flavivirus** and rhabdovirus infections may be treated by administering an interferon such as interferon α2, interferon α8 or interferon β and at least one compound selected from 5-membered cyclic nucleosides, mycophenolic compds., imidazole derivs., aminoadamantanes and 2,4-diaminopyrimidines. An example showed the enhancement of antiviral effects of interferons by cyclopentenyl cytosine.
IT **19186-33-5**, Aristeromycin
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(synergistic antiviral combination of interferons and heterocyclic compds.)
RN 19186-33-5 HCAPLUS
CN 1,2-Cyclopentanediol, 3-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)-, (1R,2S,3R,5R)- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




L24 ANSWER 34 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:242170 HCAPLUS
DOCUMENT NUMBER: 131:84756
TITLE: The 37-Amino-Acid Interdomain of Dengue Virus NS5 Protein Contains a Functional NLS and Inhibitory CK2 Site
AUTHOR(S): Forwood, Jade K.; Brooks, Andrew; Briggs, Lyndall J.; Xiao, Chong-Yun; Jans, David A.; Vasudevan, Subhash G.
CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, James Cook University of North Queensland, Townsville, Australia
SOURCE: Biochemical and Biophysical Research Communications (1999), 257(3), 731-737
CODEN: BBRCA9; ISSN: 0006-291X
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The dengue virus NS5 RNA-dependent RNA polymerase has been detected in the nucleus of virus-infected mammalian cells. We demonstrate here for the first time using in vitro and in vivo assay systems that the 37-amino-acid

linker interdomain of NS5 (residues 369 to 405) contains a nuclear localization sequence (NLS) which is capable of targeting b-galactosidase to the nucleus. Further, we show that the linker is recognized by subunits of the NLS-binding importin complex with an affinity similar to that of the bipartite NLS of the retinoblastoma protein and, in analogous fashion to proteins such as the SV40 large tumor antigen, contains a functional protein kinase CK2 phosphorylation site (threonine 395). Interestingly, this site appears to inhibit NS5 nuclear targeting, probably through a cytoplasmic retention mechanism. The linker may have an important role in targeting NS5 to the nucleus in a regulated manner during the dengue virus infectious cycle. (c) 1999 Academic Press.

IT **56-65-5**, 5'-ATP, biological studies
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); BIOL (Biological study)
(nuclear import of NS5 dependence on ATP; interdomain of dengue virus NS5 RNA-dependent RNA polymerase contains a functional NLS and inhibitory CK2 site)

RN 56-65-5 HCAPLUS
CN Adenosine 5'-(tetrahydrogen triphosphate) (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:293319 HCAPLUS
DOCUMENT NUMBER: 129:579
TITLE: Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
INVENTOR(S): Loeb, Lawrence A.; Mullins, James I.
PATENT ASSIGNEE(S): University of Washington, USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9818324 | A1 | 19980507 | WO 1997-US19670 | 19971027 |

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| AU 9850959 | A1 | 19980522 | AU 1998-50959 | 19971027 |
| AU 740916 | B2 | 20011115 | | |
| EP 948256 | A1 | 19991013 | EP 1997-913882 | 19971027 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| NZ 335000 | A | 20001222 | NZ 1997-335000 | 19971027 |
| JP 2001525797 | T2 | 20011211 | JP 1998-520739 | 19971027 |

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | US 1996-29404P | P | 19961028 |
| | US 1997-40535P | P | 19970227 |
| | WO 1997-US19670 | W | 19971027 |

AB The invention is directed to the identification and use of ribonucleoside analogs to induce the mutation of an RNA virus, including HIV and HCV, or a virus which otherwise replicates through an RNA intermediate. The increase in the mutation rate of the virus results in reduced viability of progeny generations of the virus, thereby inhibiting viral replication. In addition to these methods and related compns., the invention provides methods and combinatorial chemical libraries for screening ribonucleoside analogs for mutagenic potential.

IT **58-61-7D**, Adenosine, derivs., biological studies **118-00-3D**, Guanosine, derivs., biological studies **1867-73-8** **1867-73-8D**, derivs. **3868-31-3**, 8-Hydroxyguanosine **3868-31-3D**, 8-Hydroxyguanosine, derivs. **3868-32-4**, 8-Aminoguanosine **3868-32-4D**, 8-Aminoguanosine, derivs. **7803-88-5 7803-88-5D**, derivs. **39007-51-7** **39007-51-7D**, derivs. **39007-52-8 39007-52-8D**, derivs. **39708-01-5 39708-01-5D**, derivs. **72055-62-0**, 3-Methyladenosine **72055-62-0D**, 3-Methyladenosine, derivs. **82773-20-4 82773-20-4D**, derivs. **108060-85-1 108060-85-1D**, derivs.
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA, and screening method)

RN 58-61-7 HCAPLUS
CN Adenosine (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 118-00-3 HCAPLUS
CN Guanosine (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1867-73-8 HCAPLUS
CN Adenosine, N-methyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1867-73-8 HCAPLUS
CN Adenosine, N-methyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3868-31-3 HCAPLUS
CN Guanosine, 7,8-dihydro-8-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3868-31-3 HCAPLUS
CN Guanosine, 7,8-dihydro-8-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3868-32-4 HCAPLUS
CN Guanosine, 8-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3868-32-4 HCAPLUS
CN Guanosine, 8-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 7803-88-5 HCAPLUS
CN Guanosine, 6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 7803-88-5 HCAPLUS
CN Guanosine, 6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39007-51-7 HCAPLUS
CN 3H-Imidazo[2,1-i]purine, 3-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39007-51-7 HCAPLUS
CN 3H-Imidazo[2,1-i]purine, 3-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39007-52-8 HCAPLUS
CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39007-52-8 HCAPLUS
CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39708-01-5 HCAPLUS
CN Guanosine, 6-O-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 39708-01-5 HCAPLUS
CN Guanosine, 6-O-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 72055-62-0 HCAPLUS
CN Adenosine, 3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 72055-62-0 HCAPLUS
CN Adenosine, 3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82773-20-4 HCAPLUS
CN Guanosine, 6-O-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82773-20-4 HCAPLUS
CN Guanosine, 6-O-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 108060-85-1 HCAPLUS
CN 1H-Imidazo[2,1-b]purin-4(5H)-one, 1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 108060-85-1 HCAPLUS
CN 1H-Imidazo[2,1-b]purin-4(5H)-one, 1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:147346 HCAPLUS
DOCUMENT NUMBER: 128:213381
TITLE: Compositions and methods for treating infections using analogs of indolicidin
INVENTOR(S): Fraser, Janet R.; West, Michael H. P.; Krieger, Timothy J.; Taylor, Robert; Erfle, Douglas
PATENT ASSIGNEE(S): Micrologix Biotech, Inc., Can.; Fraser, Janet R.; West, Michael H. P.; Krieger, Timothy J.; Taylor, Robert; Erfle, Douglas
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

| | | | | |
|---|---|---|---|---|
| WO 9807745 | A2 | 19980226 | WO 1997-US14779 | 19970821 |
| WO 9807745 | A3 | 19980709 | | |
| W: AL, AM, AT, AU, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| AU 9743279 | A1 | 19980306 | AU 1997-43279 | 19970821 |
| EP 925308 | A2 | 19990630 | EP 1997-941352 | 19970821 |
| EP 925308 | B1 | 20020605 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2001500477 | T2 | 20010116 | JP 1998-510994 | 19970821 |
| EP 1174439 | A2 | 20020123 | EP 2001-119148 | 19970821 |
| EP 1174439 | A3 | 20030326 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| AT 218579 | E | 20020615 | AT 1997-941352 | 19970821 |
| ES 2178000 | T3 | 20021216 | ES 1997-941352 | 19970821 |
| HK 1021824 | A1 | 20030221 | HK 1999-106212 | 19991230 |
| US 2004009910 | A1 | 20040115 | US 2003-351985 | 20030124 |

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | US 1996-24754P | P | 19960821 |
| | US 1997-34949P | P | 19970113 |
| | US 1997-915314 | A1 | 19970820 |
| | EP 1997-941352 | A3 | 19970821 |
| | WO 1997-US14779 | W | 19970821 |
| | US 2000-667486 | A1 | 20000922 |

OTHER SOURCE(S): MARPAT 128:213381

AB Compns. and methods for treating infections, especially bacterial infections, are provided. Indolicidin peptide analogs containing at least two basic amino acids are prepared The analogs are administered as modified peptides, preferably containing photo-oxidized solubilizer.

IT **5536-17-4**, Vidarabine
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(indolicidin analogs, and combinations with other agents, for treating infections)

RN 5536-17-4 HCAPLUS

CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L24 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:810683 HCAPLUS
DOCUMENT NUMBER: 123:188560
TITLE: ATP as inhibitor of viruses in relation to rabies and West Nile viruses
INVENTOR(S): Votyakov, Veniamin I.; Mishaeva, Nina P.; Zubovich, Irina K.; Azarova, Irina A.
PATENT ASSIGNEE(S): Belorusskij Nauchno-Issledovatelskij Institut Epidemiologii i Mikrobiologii, USSR
SOURCE: U.S.S.R. From: Izobreteniya 1993, (26), 14. CODEN: URXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| SU 1827251 | A1 | 19930715 | SU 1990-4780028 | 19900108 |

PRIORITY APPLN. INFO.: SU 1990-4780028 19900108
AB Title only translated.
IT **56-65-5**, 5'-ATP, biological studies
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(ATP as inhibitor of viruses in relation to rabies and West Nile viruses)
RN 56-65-5 HCAPLUS
CN Adenosine 5'-(tetrahydrogen triphosphate) (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




L24 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1994:595323 HCAPLUS
DOCUMENT NUMBER: 121:195323
TITLE: Immunotherapy of viral encephalitis: use of polyinosinic polycytidylic acid in prophylaxis and therapy of Banzi virus encephalitis
AUTHOR(S): Barnhart, Dean Co.
CORPORATE SOURCE: University of South Carolina, SC, USA
SOURCE: (1993) 143 pp. Avail.: Univ. Microfilms Int., Order No. DA9400188
From: Diss. Abstr. Int. B 1994, 55(1), 71
DOCUMENT TYPE: Dissertation
LANGUAGE: English

AB Unavailable

IT **24939-03-5**, Polyriboinosinic polyribocytidylic acid
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(polyinosinic polycytidylic acid in prophylaxis and therapy of Banzi virus encephalitis)

RN 24939-03-5 HCAPLUS

CN 5'-Inosinic acid, homopolymer, complex with 5'-cytidylic acid homopolymer (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 30918-54-8
CMF (C10 H13 N4 O8 P)x
CCI PMS

CM 2

CRN 131-99-7
CMF C10 H13 N4 O8 P

Absolute stereochemistry.




CM 3

CRN 30811-80-4
CMF (C9 H14 N3 O8 P)x
CCI PMS

CM 4

CRN 63-37-6
CMF C9 H14 N3 O8 P

Absolute stereochemistry.



L24 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1988:436458 HCAPLUS
DOCUMENT NUMBER: 109:36458
TITLE: Comparative study of various immunomodulators for macrophage and natural killer cell activation and antiviral efficacy against exotic RNA viruses
AUTHOR(S): Pinto, Angelo J.; Morahan, Page S.; Brinton, Margo A.
CORPORATE SOURCE: Dep. Microbiol. Immunol., Med. Coll. Pennsylvania, Philadelphia, PA, 19129, USA
SOURCE: International Journal of Immunopharmacology (1988), 10(3), 197-209
CODEN: IJIMDS; ISSN: 0192-0561
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Several immunomodulators were compared for immunomodulatory and antiviral activity in B6C3F1 female mice. Murine recombinant γ-interferon (rIFN-G), human recombinant alpha A/D interferon (rIFN-A), ampligen (a polyribonucleotide) and CL246,738 modulate nonspecific immunity and are effective antiviral agents in vivo. Administration of each of these agents 1 day before cell harvest induced high levels of splenic natural killer (NK) cell activity against YAC-1 target cells. The rIFN-G was also a potent activator of peritoneal macrophages (M.vphi.), as evidenced by high levels of antitumor activity and changes in ectoenzyme phenotype that is characteristic of tumoricidal M.vphi.. RIFN-A, ampligen and CL246,738 induced moderate to low levels of M.vphi. activation by these criteria. In vivo protection expts. showed that repeated therapeutic treatment with rIFN-A protected mice against i.p. infection with Venezuelan equine encephalitis virus (an alpha togavirus, VEE), Banzi virus (a **flavivirus**) and herpes simplex virus type 2 (HSV-2). Similar treatment with rIFN-G was effective against VEE and HSV-2, but ineffective against Banzi virus. A single prophylactic i.p. dose of ampligen 1 day before virus challenge was very effective against Banzi virus, moderately effective against HSV-2, and ineffective against VEE and Caraparu virus (a bunyavirus) infection. A single prophylactic oral dose of CL246,738 provided almost complete protection of mice against VEE, Banzi, and HSV-2, and also increased the mean survival time for Caraparu virus-infected mice. These results indicate that rIFN-A, r-IFN-G, ampligen and CL246,738 may be useful in prophylactic or early therapeutic treatment of several serious virus infections. Since these agents stimulate NK cells and M.vphi., their antiviral activity may result, in part, from the alterations they induce in the natural immune system.

IT **38640-92-5**, Ampligen
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); BIOL (Biological study)
(antiviral activity of, macrophage and natural killer cell activation in)
RN 38640-92-5 HCAPLUS
CN 5'-Inosinic acid, homopolymer, complex with 5'-cytidylic acid polymer with 5'-uridylic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 30918-54-8
CMF (C10 H13 N4 O8 P)x
CCI PMS

CM 2

CRN 131-99-7
CMF C10 H13 N4 O8 P

Absolute stereochemistry.



CM 3

CRN 26427-29-2
CMF (C9 H14 N3 O8 P . C9 H13 N2 O9 P)x
CCI PMS

CM 4

CRN 63-37-6
CMF C9 H14 N3 O8 P

Absolute stereochemistry.



CM 5

CRN 58-97-9
CMF C9 H13 N2 O9 P

Absolute stereochemistry.



L24 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1981:562106 HCAPLUS
DOCUMENT NUMBER: 95:162106
TITLE: Interferon inducing and antiviral activity of levamisole
AUTHOR(S): Ershov, F. I.; Grigoryan, S. S.; Kremerman, I. B.; Nikolaeva, O. V.
CORPORATE SOURCE: D. I. Ivanovskii Inst. Virol., Moscow, USSR
SOURCE: Antibiotiki (Moscow) (1981), 26(8), 617-20
CODEN: ANTBAL; ISSN: 0003-5637
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB The median LD of levamisole-HCl (I) [16595-80-5] for mice was 900 mg/kg orally. Mice receiving 100 mg I/kg orally showed blood interferon of 320-640 units/mL in 5-6 h, after which it fell to 80 units/mL and remained at this level for 5 days. Simultaneous administration of I and another interferon inducer polyguacil [25280-45-9] showed that the 2 compds. were additive in their inducing ability. I at 100 mg/kg protected 35-40% of mice when given 4 or 24 h before infection with a 10 + LD50 dose of Russian tick-borne encephalitis and 15% of mice when given 4 h before a 10 + LD50 dose of influenza virus.

IT **25280-45-9**
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); BIOL (Biological study)
(antiviral and interferon inducing activity of)
RN 25280-45-9 HCAPLUS
CN 5'-Guanylic acid, homopolymer, complex with 5'-cytidylic acid homopolymer (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 30811-80-4
CMF (C9 H14 N3 O8 P)x
CCI PMS

CM 2

CRN 63-37-6
CMF C9 H14 N3 O8 P

Absolute stereochemistry.




CRN 25191-14-4
CMF (C10 H14 N5 O8 P)x

CCI PMS

CM 4

CRN 85-32-5
CMF C10 H14 N5 O8 P

Absolute stereochemistry.




L24 ANSWER 41 OF 41 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1977:462689 HCAPLUS
DOCUMENT NUMBER: 87:62689
TITLE: Study of the antiviral activity of a complex of poly-I-poly-C with poly-L-lysine in monkeys
AUTHOR(S): Burgasova, M. P.
CORPORATE SOURCE: Moscow Res. Inst. Viral Prep., Moscow, USSR
SOURCE: Antibiotiki (Moscow) (1977), 22(5), 458-60
CODEN: ANTBAL; ISSN: 0003-5637
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB S. c. injection of the interferon-inducing complex of double stranded poly I-poly C with poly-L-lysine decreased the intensity and duration of skin affections and increased the incubation period of variolovaccine in s.c. infected rhesus monkeys; i.v. injection of the complex was less effective. The complex also showed some prophylactic activity against tick-borne encephalitis in rheus monkeys.

IT **24939-03-5D**, poly-L-lysine complexes
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(virucidal activity of)

RN 24939-03-5 HCAPLUS
CN 5'-Inosinic acid, homopolymer, complex with 5'-cytidylic acid homopolymer (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 30918-54-8
CMF (C10 H13 N4 O8 P)x
CCI PMS

CM 2

CRN 131-99-7
CMF C10 H13 N4 O8 P

Absolute stereochemistry.



CM 3

CRN 30811-80-4
CMF (C9 H14 N3 O8 P)x
CCI PMS

CM 4

CRN 63-37-6
CMF C9 H14 N3 O8 P

Absolute stereochemistry.